The anti-bladder cancer activity of oxymatrine was recently discovered: Oxymatrine dose-dependently suppresses the proliferation of bladder cancer cells, arrests the cell cycle, and triggers apoptosis through Bax and caspase 3 upregulation and downregulation of p53, Bcl-2, and survivin expression in T24 bladder cancer cells (94). The gene discussed is BCL2; the disease is urinary bladder carcinoma.